Our Technology
Zeta Therapeutics
Ovarian Cancer, Peritoneal Carcinomatosis
Zeta Therapeutics
Our Nanotechnology, 
Key Publications
Zeta Therapeutics
Our Nanotechnology, 
Key Publications
Our Nanotechnology
In 2014 the US National Academy of Engineering identified ‘Engineering Better Medicines’ as one of the fourteen Grand Challenges for Engineering. Although there are many ways that better medicines could be engineered, one of the most promising concepts to emerge in recent years is the utilisation of nanoparticle technologies to improve the quality of life for cancer patients.

Nanoparticles are neither molecules nor bulk solids, but exhibit their own unique characteristics that can be tailored to enable specific interactions with cells. In this way, nanoparticles offer the potential of great versatility in designing different therapeutic concepts. The Zeta Therapeutics nanoparticles are sized between 10 and 100 nm, i.e. larger than a protein but smaller than a flu virus, as can be seen from the diagram below.

Our Nanotechnology

In 2014 the US National Academy of Engineering identified ‘Engineering Better Medicines’ as one of the fourteen Grand Challenges for Engineering. Although there are many ways that better medicines could be engineered, one of the most promising concepts to emerge in recent years is the utilisation of nanoparticle technologies to improve the quality of life for cancer patients.

Nanoparticles are neither molecules nor bulk solids, but exhibit their own unique characteristics that can be tailored to enable specific interactions with cells. In this way, nanoparticles offer the potential of great versatility in designing different therapeutic concepts. The Zeta Therapeutics nanoparticles are sized between 10 and 100 nm, i.e. larger than a protein but smaller than a flu virus, as can be seen from the diagram below.
Our Nanotechnology
In 2014 the US National Academy of Engineering identified ‘Engineering Better Medicines’ as one of the fourteen Grand Challenges for Engineering. Although there are many ways that better medicines could be engineered, one of the most promising concepts to emerge in recent years is the utilisation of nanoparticle technologies to improve the quality of life for cancer patients.

Nanoparticles are neither molecules nor bulk solids, but exhibit their own unique characteristics that can be tailored to enable specific interactions with cells. In this way, nanoparticles offer the potential of great versatility in designing different therapeutic concepts. The Zeta Therapeutics nanoparticles are sized between 10 and 100 nm, i.e. larger than a protein but smaller than a flu virus, as can be seen from the diagram below.
At Zeta Therapeutics we utilize RAFT (Reversible Addition-Fragmentation chain Transfer) to produce fantastically robust and effective polymer coatings, firmly anchored onto our nanoparticle cores so they remain stably dispersed even when diluted in relatively hostile biological environments. This is important because it means the special characteristics that we have designed into our nanoparticles remain unchanged throughout their journey from manufacture to being internalized into a patient’s cancer and finally being eliminated once their job is done. 

We consider this a platform technology that we can adapt to design functionalized coatings to achieve whatever purpose we require. In the case of ZTX018 we have formulated a coating for our iron oxide core particles that will ensure they effectively concentrate in a patient’s metastatic ovarian cancer nodules where they will amplify the effectiveness of chemotherapy drugs such as cisplatin and paclitaxel.
At Zeta Therapeutics we utilize RAFT (Reversible Addition-Fragmentation chain Transfer) to produce fantastically robust and effective polymer coatings, firmly anchored onto our nanoparticle cores so they remain stably dispersed even when diluted in relatively hostile biological environments. This is important because it means the special characteristics that we have designed into our nanoparticles remain unchanged throughout their journey from manufacture to being internalized into a patient’s cancer and finally being eliminated once their job is done. 

We consider this a platform technology that we can adapt to design functionalized coatings to achieve whatever purpose we require. In the case of ZTX018 we have formulated a coating for our iron oxide core particles that will ensure they effectively concentrate in a patient’s metastatic ovarian cancer nodules where they will amplify the effectiveness of chemotherapy drugs such as cisplatin and paclitaxel.

At Zeta Therapeutics we utilize RAFT (Reversible Addition-Fragmentation chain Transfer) to produce fantastically robust and effective polymer coatings, firmly anchored onto our nanoparticle cores so they remain stably dispersed even when diluted in relatively hostile biological environments. This is important because it means the special characteristics that we have designed into our nanoparticles remain unchanged throughout their journey from manufacture to being internalised into a patient’s cancer and finally being eliminated once their job is done. 


We consider this a platform technology that we can adapt to design functionalized coatings to achieve whatever purpose we require. In the case of ZTX018 we have formulated a coating for our iron oxide core particles that will ensure they effectively concentrate in a patient’s metastatic ovarian cancer nodules where they will amplify the effectiveness of chemotherapy drugs such as cisplatin and paclitaxel.

Share by: